

# Molecular Diagnostics: Market Research Report

<https://marketpublishers.com/r/M8346E814A7EN.html>

Date: December 2018

Pages: 570

Price: US\$ 5,600.00 (Single User License)

ID: M8346E814A7EN

## Abstracts

This report analyzes the worldwide markets for Molecular Diagnostics in US\$ Thousand by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 137 companies including many key and niche players such as -

Abbott Laboratories

Becton, Dickinson and Company

bioMérieux SA

Cepheid

F. Hoffmann-La Roche Ltd.

Grifols International, S.A.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. GLOBAL MARKET OVERVIEW

Global In-Vitro Diagnostics (IVD) Market on a Steady Growth Path

**Table 1.** Global In-Vitro Diagnostics Market by Segment (2017): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)

**Table 2.** Global In-Vitro Diagnostics Market by Geographic Region (2017): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart)

Molecular Diagnostics – A Rapidly Expanding Segment of the IVD Market

PCR Technology Leads the MDx Market

Current and Future Analysis

Leading Players

US and Europe – Leaders in Molecular Diagnostics Adoption

Developing Countries Excel in Growth Prospects

Major Growth Drivers

Key Market Trends in a Nutshell

Major Technology Trends

Oncology Molecular Diagnostics to Witness Rapid Growth...

Reagents and Kits Dominate the Molecular Diagnostics Market

Based on Test Location

Product Innovations Rife in POC Molecular Diagnostics Market

Advancements in Molecular Diagnostics – A Boon for the Industry  
Major Challenges  
Market Outlook

## **2. GROWTH DRIVERS AND MARKET TRENDS**

Aging Population Drives Molecular Diagnostics Market  
Global Aging Population Statistics – Opportunity Indicators

**Table 3.** Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)

**Table 4.** Global Population Statistics for the 60+ Age Group by Region: 2017 (includes corresponding Graph/Chart)

**Table 5.** Global Population Statistics for the 65+ Age Group by Select Countries: 2016 (includes corresponding Graph/Chart)

**Table 6.** Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

Technological Innovations Set to Drive the Market  
The Role of Molecular Diagnostics in Personalized Medicine  
Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area

**Table 7.** Leading Personalized Medicines Worldwide (2015-2017): Annual Sales of Select Leading Medicines in US\$ Million (includes corresponding Graph/Chart)

Companion Diagnostics Drive Personalized Medicine  
List of FDA Approved Complementary and Companion Diagnostic Assays  
Biomarkers as Companion Diagnostics  
Rise in Healthcare Spending in Developing Nations Bode Well for Market Growth

**Table 8.** Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)

**Table 9.** Per-Capita Healthcare Expenditure in US\$ for Select Countries/Regions (2016)  
(includes corresponding Graph/Chart)

Proteomics Technologies: Growing in Significance  
New Developments in Proteomics Technologies  
New Applications Hold Promising Potential  
Molecular Diagnostics for Lymphoid Malignancies  
Next-Generation Sequencing (NGS) Technologies Keep Up the Momentum  
Select NGS Platforms Available in the Market  
Rising Emphasis on Lab Automation to Augur Well for Market Growth  
List of Fully Automated and Rapid Molecular Diagnostics  
Molecular Diagnostics and Intellectual Property  
Molecular Diagnostics – Moving from Centralization to Decentralization  
Limited Reimbursements by Third Party Payers – A Stumbling Block

### **3. APPLICATION AREAS OF MOLECULAR DIAGNOSTICS**

Infectious Diseases  
Bright Prospects Ahead for Molecular Diagnostics for Testing Infectious Diseases  
Leading Players  
Key Trends  
Increasing Incidence of Infectious Diseases Fuels Adoption  
Rising Incidence of Hospital Acquired Infections Propels Market Growth

**Table 10.** Comparison of Different Parameters for Select C. diff MDx Tests

Rising HIV Prevalence Provides Ample Growth Opportunities

**Table 11.** HIV Prevalence and Incidence Statistics by Region: 2016 (includes corresponding Graph/Chart)

**Table 12.** HIV Prevalence among the Global Adult Population: 2011-2016

**Table 13.** Regional Data about HIV and AIDS (2016)

Infectious Disease Testing – A Major Driver of Molecular Diagnostics Market  
Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases

Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market  
Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing  
HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market  
List of Select HPV Molecular Diagnostic Tests by Company and Technique  
Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing  
Major Risk Factors to HPV/Cervical Cancer

**Table 14.** Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart)

**Table 15.** World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart)

**Table 16.** Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in '000s) (includes corresponding Graph/Chart)

HPV Testing for Primary Screening Indication Bodes Well for the Market's Growth  
Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics  
List of Select Commercially-Available TB Diagnostics  
An Overview of Select TB Diagnostics  
Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential...  
PCR Plays a Vital Role in the Diagnosis of Infectious Diseases  
Blood Screening  
Molecular based Tests Ingrain Roots in Blood Donor Screening Segment  
Cancer Screening & Diagnosis  
Overview  
Molecular Tests Lead the Way for Cancer IVD Market Growth  
Molecular Markers to Enhance Thyroid Cancer Diagnosis  
Oncology-Based Molecular Diagnostics: The Propitious Segment  
List of US-FDA Approved Biomarkers for Cancer

**Table 17.** Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)

**Table 18.** Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)

Growing Popularity of Chemo-Sensitivity Testing of CTCs  
Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers  
Other Testing Applications  
Genetic Disease Testing Applications  
Overview  
Pharmacogenomics – Prognosis Based on Genomics  
Pharmacogenomics Development Augurs Growth of Genetic Testing Market  
Prospects for Genetic Diagnostics and Testing Grow Brighter  
List of Select FDA-Cleared Genetic Tests by Disease  
Genetic Testing – An Indispensable Tool for Cystic Fibrosis

**Table 19.** Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)

Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions  
Non-Invasive Prenatal Diagnostics – The Way Ahead  
Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance  
PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents

#### **4. COMPETITION IN THE MOLECULAR DIAGNOSTICS MARKET**

An Overview of Competitive Landscape in Molecular Diagnostics

**Table 20.** Global Molecular Diagnostics Market by Leading Player (2017): Percentage Share Breakdown by Value Sales for Roche, Qiagen, Abbott, GenProbe, Siemens, and Others (includes corresponding Graph/Chart)

Other Noteworthy Companies  
Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market  
Qiagen: The Leading Player in the Global HPV MDx Market  
Comparative Analysis of Select HPV MDx Tests  
Competitive Dynamics in the *C. difficile* Testing Market

**Table 21.** Global Molecular Diagnostics Market for *Clostridium difficile* by Leading Player (2017): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian, and Others (includes corresponding Graph/Chart)

List of Select Molecular C. difficile Test Products  
Competition in the Blood Screening MDx Market

**Table 22.** Global Blood Screening MDx Market by Leading Players (2017): Percentage Market Share Breakdown of Value Sales for Grifols, Roche, and Others (includes corresponding Graph/Chart)

Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market  
Competitive Landscape in the Global RT-PCR Market

**Table 23.** Leading Players in Global RT-PCR Instruments Market (2017): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Thermo Fischer, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)

Select Real-Time PCR Products by Company  
Competition Heats Up in dPCR Market

**Table 24.** Leading dPCR Systems at a Glance

Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market  
Consolidation Activity Continues to Strengthen Driven by New Entrants  
Major M&A Transactions in Molecular Diagnostics: 2011-2018

## **5. PRODUCT & TECHNOLOGY OVERVIEW**

Molecular Diagnostics – Definition & Scope  
Molecular Diagnostics – Impact on Healthcare  
Utility of Molecular Diagnostic Tests  
Background of Molecular Diagnostics  
Types of Molecular Diagnostics  
Conventional Diagnostics Vs. Molecular Diagnostics  
Unabated Developments in Molecular Diagnostics Technology  
Signal Amplification Technologies  
PCR – New Developments  
Quantitative Real-Time PCR for Molecular Diagnostics

Signal Detection and Quantification  
Quantitative Real-Time RT-PCR Analysis  
Applications of Quantitative Real-Time PCR Analysis  
Digital PCR  
Non-PCR Methods  
Other Signal Amplification Technologies  
DNA Probe Based Products  
Direct Detection of Specific Nucleic Acid Sequences  
Nucleic Acid Amplification and Detection  
DNA Sequencing and Gene Detection  
Arrays of Immobilized Probes (DNA Chips) in Gene Detection  
RNA Diagnostics  
Complementary Molecular Diagnostic Technologies  
Fluorescent In-Situ Hybridization (FISH)  
DNA Biochips/Microarrays  
Biosensors  
Proteomic Technologies for Molecular Diagnostics  
Nanotechnology for Molecular Diagnostics  
Technologies on the Anvil  
Haplotype Analysis – A Distant Possibility  
Chronic Multi-Gene Defects Now Diagnosable  
Whole Genome Sequencing – A Boon or a Bane to Genetic Testing?

## **6. PRODUCT APPROVALS/INTRODUCTIONS**

Mobidiag Unveils Novodiag Solution  
QIAGEN Unveils QFT-Plus  
Interpace Diagnostics Launches Lung Cancer Test  
Selfdiagnostics Introduces STD Multitest  
Multiplicom Releases Extended CE-IVD Certification for all BRCA Testing Needs  
Admera Health Introduces OncoGxSelect at the AMP 2016 Annual Meeting  
Interpace Diagnostics Launches Two New Thyroid Services  
Abbott Completes the Launch of Alinity  
Bio-Rad Introduces Amplichek I Quality Control  
Qiagen Introduces New Diagnostic Test for Cervical Cancer  
GE Showcases Discovery MI and Discovery NM/CT 670 CZT  
Quest Launches New Tests for Determining Hereditary Cancer  
Predictive Launches Test for Spine Deformities  
LabCorp Introduces Epi proColon



Agena Rolls Out MassARRAY Dx  
Rosetta Introduces Three New Diagnostic Offerings

## **7. RECENT INDUSTRY ACTIVITY**

Randox Partner with Bosch to Introduce Vivalytic  
Eurofins Acquires NMDL-LCPL  
QIAGEN N. V Acquires STAT-Dx  
Siemens Healthineers Acquires Fast Track Diagnostics  
General Atomics Buys Assets of Xagenic, Inc  
QIAGEN Establish Custom Solutions Business  
Abbott Acquires Alere, Inc  
Biocartis Extends Partnership with ETPL  
Agilent Technologies Signs Agreement with Agendia on Molecular Cancer Diagnostics  
AID Partners Capital Takes over Israeli Medical Diagnostic  
Agilent Technologies Acquires Multiplicom N. V  
ELITechGroup agrees with Abbott's Molecular Business, for Distributing Molecular Diagnostic Reagents  
Miragen Therapeutics and Signal Genetics Agrees to Merge  
New England Biolabs Agrees with AmpTec GmbH for Supplying key mRNA Synthesis Reagents  
Seegene and Hamilton Signs Agreement for Developing Molecular Diagnostics System  
Transgenomic and Precipio Diagnostics Agrees to Merge  
Sedia Biosciences and Florgenex Completes Merger  
Interpace Diagnostics Group Completes the Launch of PanDNA  
WuXi AppTec's Laboratory Testing Division Enters into a Distributor Agreement with AutoGenomics  
Danaher Corporation Enters into Merger Agreement with Cepheid  
Interpace Diagnostics Group, Inc. Extends Agreement with LabCorpLH  
Agilent Technologies Agrees with Burning Rock to Develop Cancer Diagnostics in China  
Bio-Techne to Acquire Advanced Cell Diagnostics  
Myriad Acquires Sividon Diagnostics  
Siemens Acquires Neo New Oncology  
Luminex to Acquire Nanosphere  
DiaSorin Completes Acquisition of Focus Diagnostics  
Avant Acquires Amaranthus Diagnostics  
HTG to Collaborate With Bristol-Myers Squibb  
Miroculus to Acquire Kapplex

Cepheid's Xpert MRSA NxG Gets European Approval  
SpeedX Collaborates with Goffin Molecular  
FDA Approves BD's Totalys  
BioFire Diagnostics' FilmArray Obtains CE Mark Approval  
Thermo Fisher Acquires Affymetrix  
Qiagen Collaborates with Mirati  
BioGenex to Commence Operations from India Center  
Illumina Collaborates with investors to Launch GRAIL

## 8. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)  
Abbott Molecular (USA)  
Becton, Dickinson and Company (USA)  
bioMérieux SA (France)  
Cepheid (USA)  
F. Hoffmann-La Roche Ltd. (Switzerland)  
Grifols International, S. A. (Spain)  
Hologic, Inc. (USA)  
QIAGEN N. V. (The Netherlands)  
QuestDiagnostics, Inc. (USA)  
Siemens Healthcare GmbH (Germany)  
Tecan Group Ltd. (Switzerland)  
The ELITechGroup (France)  
Thermo Fisher Scientific (USA)

## 9. GLOBAL MARKET PERSPECTIVE

**Table 25.** World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 26.** World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 27.** World 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

Molecular Diagnostics Market by Application

**Table 28.** World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 29.** World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 30.** World 14-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

**Table 31.** World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 32.** World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 33.** World 14-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

**Table 34.** World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 35.** World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 36.** World 14-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

**Table 37.** World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 38.** World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 39.** World 14-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

### **III. MARKET**

## 1. THE UNITED STATES

### A. Market Analysis

US Molecular Diagnostics Market Maintain its Growth Momentum

**Table 40.** Diagnoses of HIV Infection in the US (2015 & 2016) (includes corresponding Graph/Chart)

**Table 41.** AIDS Stage 3 Diagnoses in the US (2011-2016) (includes corresponding Graph/Chart)

**Table 42.** New Cancer Cases in the US by State (2017E) (includes corresponding Graph/Chart)

**Table 43.** Number of Deaths Related to Major Types of Cancer in US by State: 2017E (includes corresponding Graph/Chart)

### Competitive Landscape

qPCR and dPCR Instrumentation in the US: An Overview

Ageing Demographics: Major Driving Factor

**Table 44.** Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

**Table 45.** North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Increasing Incidence of Chronic Diseases Drives Focus onto Molecular Diagnostics

US Personalized Medicine Market to Witness Significant Growth

Companion Diagnostics Market in the US

List of FDA Approved Complementary and Companion Diagnostic Assays

Burgeoning Potential for Genetic Testing

Direct-to-Consumer Testing – A Growing Market

Epidemic Proportion of Cancer in the US – Key Driver for Cancer Genetic Testing

**Table 46.** New Cancer Cases by Gender and Affected Site in the US (2017E) (includes

corresponding Graph/Chart)

**Table 47.** Cancer Related Deaths by Gender and Affected Site in the US (2017E)  
(includes corresponding Graph/Chart)

Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing  
List of FDA-Cleared CF MDx Tests  
Molecular Diagnostics Tests Gaining Share in STD Testing Domain  
HPV Testing Market – A Review

**Table 48.** Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)

**Table 49.** Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart)

Competitive Landscape  
List of FDA Approved HPV MDx Tests  
Regulatory Environment  
FDA Regulations  
Clinical Laboratory Improvement Amendments (CLIA)

**Table 50.** Number of CLIA-Certified Laboratories in the US by Certificate Type:  
(January 2018) (includes corresponding Graph/Chart)

**Table 51.** CLIA-Certified Laboratories in the US (2018): Percentage Share Breakdown  
of Number of Labs by Lab Type (includes corresponding Graph/Chart)

Genetic Testing  
FDA to Implement Strict Measures for Cervical Cancer Screening Tests  
Limited Reimbursements – A Major Hindrance  
New MoPath Codes for Reimbursement for Molecular Diagnostics Tests  
Product Launches/Approvals  
Strategic Corporate Developments  
Select Key Players  
B. Market Analytics

**Table 52.** The US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 53.** The US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 54.** The US 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## **2. CANADA**

### A. Market Analysis

#### Cancer Incidence in Canada: Opportunity Indicator

**Table 55.** New Cancer Cases in Canada (2017E): Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)

**Table 56.** New Cancer Cases in Canada by Province: 2017E (includes corresponding Graph/Chart)

**Table 57.** New Cancer Cases in Canada by Age Group: 2017E (includes corresponding Graph/Chart)

**Table 58.** Cancer Related Deaths in Canada (2017E): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart)

### B. Market Analytics

**Table 59.** Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in

US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 60.** Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 61.** Canadian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

### 3. JAPAN

#### A. Market Analysis

Current and Future Analysis

Demographics Drive Market Growth

**Table 62.** Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)

**Table 63.** Japanese Population by Age Group (2017E): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 65 Years and Above (includes corresponding Graph/Chart)

#### B. Market Analytics

**Table 64.** Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 65.** Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)



**Table 66.** Japanese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 4. EUROPE

### A. Market Analysis

#### Current and Future Analysis

#### Insight into Molecular Diagnostics Markets in Europe

**Table 67.** Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)

#### Regulatory Scenario in Europe for Companion Diagnostics

#### Companion Diagnostics: Select European Players with Strong Biomarker Pipeline

#### The Need for Improving Reimbursement Policies

#### Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics

**Table 68.** EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)

#### PCR Reagents in Europe: An Overview

#### Automated Systems Gain Preeminence

#### Oncology-based Molecular Diagnostics Holds Immense Potential

**Table 69.** Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)

#### Europe Heading towards Massive Improvements in Personalized Medicine

#### Personalized Medicine Big on EU Agenda – A Peek into EC Investments in This Space

#### HPV Testing in Europe: An Overview

**Table 70.** HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)

**Table 71.** HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)

**Table 72.** HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)

**Table 73.** HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)

List of Select CE-Marked HPV Molecular Diagnostic Tests  
Cervical Cancer Screening in Europe – A Review

**Table 74.** Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart)

**Table 75.** Cervical Cancer Incidence and Mortality in European Countries (2012)

**Table 76.** Prevalence of Cervical Cancer in European Countries (2012)

Strategic Corporate Development  
B. Market Analytics

**Table 77.** European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 78.** European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 79.** European 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

**Table 80.** European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 81.** European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 82.** European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

#### **4A. FRANCE**

##### A. Market Analysis

Current and Future Analysis

Product Launch

Select Key Players

##### B. Market Analytics

**Table 83.** French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 84.** French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 85.** French 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 4B. GERMANY

### A. Market Analysis

Current and Future Analysis

Product Launches

Strategic Corporate Development

Siemens Healthcare GmbH (Germany) – A Key Player

### B. Market Analytics

**Table 86.** German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 87.** German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 88.** German 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 4C. ITALY

### A. Market Analysis

Current and Future Analysis

Strategic Corporate Development

### B. Market Analytics

**Table 89.** Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 90.** Italian Historic Review for Molecular Diagnostics by Application - Infectious

Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 91.** Italian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

##### A. Market Analysis

Current and Future Analysis

Strategic Corporate Development

##### B. Market Analytics

**Table 92.** The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 93.** The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 94.** The UK 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

##### A. Market Analysis

Current and Future Analysis

Spain – Poised to become a Reckoning Force in Personalized Medicines

Grifols International, S. A. (Spain) – A Key Player

##### B. Market Analytics

**Table 95.** Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 96.** Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 97.** Spanish 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

#### **4F. RUSSIA**

##### Market Analysis

**Table 98.** Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 99.** Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 100.** Russian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

#### **4G. REST OF EUROPE**

- A. Market Analysis
  - Current and Future Analysis
  - Product Launch/Approval
  - Strategic Corporate Developments
  - Key Players
- B. Market Analytics

**Table 101.** Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 102.** Rest of Europe Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 103.** Rest of Europe 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 5. ASIA-PACIFIC

- A. Market Analysis
  - A Prelude into Asia-Pacific Market:
  - Healthcare Spending in Asia-Pacific: On the Rise
  - In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities
  - Molecular Diagnostics Testing Opens New World of Possibilities
  - Recent Advancements in Molecular Diagnostics Market: A Quick Review
  - Novel Genetic Testing Methods
  - Development of Personalized Healthcare Approaches
  - Molecular Painting for Genetic Diagnosis of Diseases
  - New Technique to Detect H1N1 Virus
- B. Market Analytics

**Table 104.** Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 105.** Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 106.** Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

**Table 107.** Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 108.** Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 109.** Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## **5A. CHINA**

### A. Market Analysis

#### Current and Future Analysis

#### In-Vitro Diagnostics Market on the Growth Curve

#### HPV Testing in China: An Overview

#### Government Support Drives Personalized Medicine Market in China

#### Strategic Corporate Development

### B. Market Analytics



**Table 110.** Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 111.** Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 112.** Chinese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## **5B. REST OF ASIA-PACIFIC**

### A. Market Analysis

Current and Future Analysis

A Focus on the Indian Molecular Diagnostics Market

Molecular Diagnostic Market in India to Witness Significant Growth

Growth Drivers in a Nut Shell

Growing Investments in Pharmacogenomics Research Drives Personalized Medicine

Indian Scientific Research towards Functional Genomics and Proteomics

Automation – The Emerging Trend in IVD Industry

HPV Testing Market: An Overview

**Table 113.** HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart)

Strategic Corporate Developments

### B. Market Analytics

**Table 114.** Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer

Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 115.** Rest of Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 116.** Rest of Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 6. LATIN AMERICA

### A. Market Analysis

Current and Future Analysis

Brazilian IVD Market on the Rise

### B. Market Analytics

**Table 117.** Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 118.** Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 119.** Latin American 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## 7. REST OF WORLD

## A. Market Analysis

Current and Future Analysis

## B. Market Analytics

**Table 120.** Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 121.** Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 122.** Rest of World 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 137 (including Divisions/Subsidiaries - 158)

The United States (95)

Canada (3)

Japan (1)

Europe (47)

France (5)

Germany (11)

The United Kingdom (9)

Italy (2)

Spain (1)

Rest of Europe (19)

Asia-Pacific (Excluding Japan) (11)

Middle East (1)

## I would like to order

Product name: Molecular Diagnostics: Market Research Report

Product link: <https://marketpublishers.com/r/M8346E814A7EN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M8346E814A7EN.html>